Merck and Hanmi Pharmaceutical have entered into an agreement to develop, manufacture and commercialize Efinopegdutide for the treatment of non-alcoholic steato-hepatitis. Merck will be licensed to develop and distribute the end product in the United States and around the world. The company will pay Hanmi up to $860 million if the development of the drug is completed successfully and it is approved for use. Hanmi also reserves the right to sell the medicine in Korea.